Stevanato Group SpA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IT0005452658
USD
22.92
-0.44 (-1.88%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

320.7 k

Shareholding (Mar 2025)

FII

21.15%

Held by 77 FIIs

DII

24.26%

Held by 62 DIIs

Promoter

0.00%

How big is Stevanato Group SpA?

22-Jun-2025

As of Jun 18, Stevanato Group SpA has a market capitalization of 6,576.86 million, with net sales of 1,207.41 million and a net profit of 134.59 million for the latest four quarters. The balance sheet shows shareholder's funds of 1,454.19 million and total assets of 2,411.49 million.

As of Jun 18, Stevanato Group SpA has a market capitalization of 6,576.86 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the company reported net sales of 1,207.41 million and a net profit of 134.59 million for the latest four quarters ending in March 2025.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 1,454.19 million and total assets of 2,411.49 million.

Read More

What does Stevanato Group SpA do?

22-Jun-2025

Stevanato Group SpA is a mid-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $270 million and a net profit of $28 million. Key metrics include a P/E ratio of 47.00 and a market cap of approximately $6.58 billion.

Overview: <BR>Stevanato Group SpA operates in the Pharmaceuticals & Biotechnology industry and is classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 270 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 28 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 6,576.86 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 47.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.21 <BR>Return on Equity: 9.05% <BR>Price to Book: 4.30<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Stevanato Group SpA overvalued or undervalued?

20-Sep-2025

As of June 30, 2025, Stevanato Group SpA is considered attractive and potentially undervalued with a P/E ratio of 47 and strong performance, outperforming the S&P 500, while offering better value compared to peers like TransMedics and LeMaitre Vascular.

As of 30 June 2025, the valuation grade for Stevanato Group SpA moved from expensive to attractive, indicating a shift towards being undervalued. The company is currently assessed as attractive, with a P/E ratio of 47, a Price to Book Value of 4.24, and an EV to EBITDA of 26.56. In comparison, peers such as TransMedics Group, Inc. have a P/E of 50.23 and an EV to EBITDA of 37.01, while LeMaitre Vascular, Inc. shows a P/E of 49.77 and an EV to EBITDA of 33.90, suggesting that Stevanato Group may offer better value relative to its peers.<BR><BR>The stock has performed well against the S&P 500, with a year-to-date return of 25.06% compared to the S&P 500's 12.22%, and a one-year return of 38.04% versus 17.14% for the index, reinforcing the attractiveness of the stock. Overall, Stevanato Group SpA appears to be undervalued based on its current valuation metrics and strong recent performance.

Read More

Is Stevanato Group SpA technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Stevanato Group SpA's trend is mildly bullish with mixed technical indicators, having underperformed the S&P 500 recently but outperformed it year-to-date and over the past year.

As of 31 October 2025, the technical trend for Stevanato Group SpA has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD remains bullish, indicating mixed signals. The daily moving averages are mildly bullish, but the weekly KST is also mildly bearish. Overall, the indicators suggest a cautious bullish stance. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, both down 4.77% compared to the S&P's gains of 0.71% and 1.92%, respectively. However, it has outperformed the S&P 500 year-to-date and over the past year, with returns of 13.54% and 26.29% compared to the S&P's 16.30% and 19.89%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROE of 14.35%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.73 times

 
3

Healthy long term growth as Net Sales has grown by an annual rate of 25.12% and Operating profit at 96.36%

 
4

The company has declared Negative results for the last 5 consecutive quarters

5

With ROE of 9.05%, it has a attractive valuation with a 4.24 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6,967 Million (Small Cap)

stock-summary
P/E

47.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.22

stock-summary
Return on Equity

8.32%

stock-summary
Price to Book

4.25

Revenue and Profits:
Net Sales:
318 Million
(Quarterly Results - Jun 2025)
Net Profit:
34 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.52%
0%
-0.52%
6 Months
2.5%
0%
2.5%
1 Year
13.97%
0%
13.97%
2 Years
-12.65%
0%
-12.65%
3 Years
43.25%
0%
43.25%
4 Years
1.06%
0%
1.06%
5 Years
0%
0%
0.0%

Stevanato Group SpA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
25.12%
EBIT Growth (5y)
96.36%
EBIT to Interest (avg)
29.21
Debt to EBITDA (avg)
0.73
Net Debt to Equity (avg)
0.21
Sales to Capital Employed (avg)
0.69
Tax Ratio
26.07%
Dividend Payout Ratio
13.11%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
15.22%
ROE (avg)
14.35%
Valuation key factors
Factor
Value
P/E Ratio
47
Industry P/E
Price to Book Value
4.24
EV to EBIT
39.20
EV to EBITDA
26.56
EV to Capital Employed
3.67
EV to Sales
5.63
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
9.36%
ROE (Latest)
9.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 51 Schemes (54.26%)

Foreign Institutions

Held by 77 Foreign Institutions (21.15%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 13.71% vs 0.54% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 51.80% vs -40.48% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "317.70",
          "val2": "279.40",
          "chgp": "13.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "70.40",
          "val2": "48.70",
          "chgp": "44.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "0.90",
          "chgp": "111.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "10.30",
          "val2": "-1.60",
          "chgp": "743.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "33.70",
          "val2": "22.20",
          "chgp": "51.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "144.50%",
          "val2": "104.10%",
          "chgp": "4.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.77% vs 13.50% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -19.11% vs 4.79% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,194.20",
          "val2": "1,173.40",
          "chgp": "1.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "251.70",
          "val2": "290.60",
          "chgp": "-13.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.40",
          "val2": "4.70",
          "chgp": "57.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.70",
          "val2": "2.70",
          "chgp": "-385.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "127.40",
          "val2": "157.50",
          "chgp": "-19.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "140.10%",
          "val2": "175.30%",
          "chgp": "-3.52%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
317.70
279.40
13.71%
Operating Profit (PBDIT) excl Other Income
70.40
48.70
44.56%
Interest
1.90
0.90
111.11%
Exceptional Items
10.30
-1.60
743.75%
Consolidate Net Profit
33.70
22.20
51.80%
Operating Profit Margin (Excl OI)
144.50%
104.10%
4.04%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 13.71% vs 0.54% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 51.80% vs -40.48% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,194.20
1,173.40
1.77%
Operating Profit (PBDIT) excl Other Income
251.70
290.60
-13.39%
Interest
7.40
4.70
57.45%
Exceptional Items
-7.70
2.70
-385.19%
Consolidate Net Profit
127.40
157.50
-19.11%
Operating Profit Margin (Excl OI)
140.10%
175.30%
-3.52%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 1.77% vs 13.50% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -19.11% vs 4.79% in Dec 2023

stock-summaryCompany CV
About Stevanato Group SpA stock-summary
stock-summary
Stevanato Group SpA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available